Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. - Wikidata - awgldk - TriplyDB

Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents.

Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents.

http://www.wikidata.org/entity/Q38110058

about

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance Identification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene.Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.Litchi seed extract inhibits epidermal growth factor receptor signaling and growth of Two Non-small cell lung carcinoma cells Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis.The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI).Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.

P2860

Q28083239-2D2EE1A3-7BF5-423C-9CBD-DB6B237E1646 Q33793930-80276BF8-FB79-41EF-B184-2EAFE3EF916D Q35770299-A3F9696F-FA55-4668-B357-745B8853C4C3 Q35820508-56F46614-52E8-479B-8FA3-291B2DF91896 Q36241312-83AAC7A7-1905-4E89-AFC1-D41339FE19A1 Q36772120-37F69A3E-8F30-4507-B471-A2A10585ED9D Q37565381-F67818FC-53BB-4D49-A6AC-9717422DA0FC Q48083050-E7261FAD-3F3F-453E-8524-FF267303B65E Q48606434-39E1DC8F-818A-40AB-9CD2-FF4C6BE452CF

P2860

Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents.

http://www.wikidata.org/entity/Q38110058

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Acquired resistance to targete ...... new strategies and new agents.

@en

type

label

Acquired resistance to targete ...... new strategies and new agents.

@en

prefLabel

Acquired resistance to targete ...... new strategies and new agents.

@en

P1433

Q38110058-E92B3D09-080F-4D40-A298-BFFD1DA65B62

P1476

Q38110058-EBCC4293-9028-4873-B356-D195A53AD152

P2093

Q38110058-52AC5CEB-47F6-487E-91B0-889C3C2E10D5

Q38110058-A99F3916-0BAD-4B15-A328-3669A00C408A

Q38110058-DBAA69F5-7EFA-4096-866C-32585B23D980

P2860

Q38110058-0F1E4EFF-6532-4E80-9A05-385EEE7A5B39

Q38110058-0FC209E8-4A1E-4333-A47E-4A17BFF89A9B

Q38110058-15EE674A-77C6-403B-A833-4B119428CC42

Q38110058-1A28CB17-0869-47F1-B34A-DF89656304F4

Q38110058-1D717B88-C6D9-4760-AC28-842C665FEFC7

Q38110058-39D5B21E-9C00-444C-AE2B-8DDF360AB7D0

Q38110058-40B7D2A9-2724-481E-B791-546F3106967D

Q38110058-46B9F714-CD2B-4E7F-8A02-1C44B810F672

Q38110058-498CE399-61A3-43E3-8409-F2B22127EF28

Q38110058-61D79393-638C-49C8-9219-D5B42CAAED72

P31

Q38110058-435FFF7D-DEC3-4216-828C-6A927B7DE041

P356

Q38110058-B9482B57-64EA-4421-9648-042BFE535862

P577

Q38110058-167A43CB-F39E-4948-9120-39794632F0D8

P698

Q38110058-AEF4E33C-69E1-4FC4-8758-F47E486A6F9D

P932

Q38110058-CA9A71A4-8446-4944-ACCE-A9A32877CC36

P356

EDBOOK_AM.2013.33.E272

P1433

American Society of Clinical Oncology educational book / ASCO

P1476

Acquired resistance to targete ...... new strategies and new agents.

@en

P2093

Geoffrey R Oxnard

http://www.w3.org/2001/XMLSchema#string

Howard West

http://www.w3.org/2001/XMLSchema#string

Robert C Doebele

http://www.w3.org/2001/XMLSchema#string

P2860

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

P31

scholarly article

P356

10.1200/EDBOOK_AM.2013.33.E272

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23714521

http://www.w3.org/2001/XMLSchema#string

P932

4142045

http://www.w3.org/2001/XMLSchema#string